肿瘤型大段假体感染二期翻修的多中心EMSOS研究
该多中心回顾性研究纳入16个骨肉瘤中心2010年1月至2020年12月治疗的186例肿瘤型大段假体(MPR)慢性感染患者,评估二期翻修后再感染发生率,中位随访68个月,5年感染复发率39.1%、10年50.0%,难治性病原体感染和多微生物感染复发率更高。作者认为最终再植入MPR可成功,但需注意复发率高于常规假体感染。
要点
- 186例MPR慢性感染患者二期翻修后5年感染复发率39.1%、10年50.0%。
- 难治性病原体感染较非难治性感染复发率更高(p=0.019)。
- 多微生物感染亦显示更高的感染复发率(p=0.046)。
核心结论
- 作者认为,感染的MPR经二期翻修并最终再植入MPR可获得成功,但术者必须意识到其复发率高于感染的常规假体。
研究设计与样本
- 回顾性研究,纳入16个骨肉瘤中心2010年1月至2020年12月治疗的186例患者。
- 肿瘤诊断时中位年龄26岁(IQR 17至33);女性69例(37.1%),男性117例(62.9%)。
- 中位随访68个月(IQR 31至105)。
主要发现
- MPR最常见部位为股骨远端93例(50.0%)和胫骨近端53例(28.5%)。
- 多微生物感染34例(18.3%);最常见分离病原体为葡萄球菌;难治性(DTT)病原体50例(26.9%)。
- 估计5年感染复发率39.1%,10年50.0%。
- 难治性假体周围感染(PJI)较非难治性感染复发率更高(p=0.019)。
- 多微生物感染也显示更高的感染复发率(p=0.046)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to assess the incidence of reinfection in patients after two-stage revision of an infected megaprosthesis (MPR) implanted after resection of a bone tumour. METHODS: A retrospective study was carried out of 186 patients from 16 bone sarcoma centres treated between January 2010 and December 2020. The median age at the time of tumour diagnosis was 26 years (IQR 17 to 33); 69 (37.1%) patients were female, and 117 (62.9%) were male. RESULTS: A total of 186 patients with chronic MPR infections were included. Median follow-up was 68 months (IQR 31 to 105). The most represented sites of MPR were distal femur in 93 cases (50.0%) and proximal tibia in 53 cases (28.5%). Polymicrobial infections were seen in 34 cases (18.3%). The most frequent isolated pathogens were staphylococci. Difficult-to-treat (DTT) pathogens were isolated in 50 cases (26.9%). The estimated infection recurrence (IR) rate was 39.1% at five years and 50.0% at ten years. A higher IR rate was found in DTT PJI compared to non-DTT infections (p = 0.019). Polymicrobial infections also showed a higher rate of infection recurrence (p = 0.046). CONCLUSION: This study suggests that an infected MPR treated by two-stage revision and ultimately reimplantation with a MPR can be successful, but the surgeon must be aware of a high recurrence rate compared to those seen with infected conventional implants.
引用
- Sambri A, Campanacci DA, Pala E, et al. Two-stage revision for infection of oncological megaprostheses : a multicentre EMSOS study. Bone Joint J. 2025. PMID: 39889756. doi:10.1302/0301-620X.107B2.BJJ-2024-0562.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。